Drugs / PHH-1V
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05007509 | Aug → Sep 2021 | COVID-19 | Laboratorios Hipra, S.A. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05305573 | Mar → Oct 2022 | COVID-19 | Hipra Scientific, S.L.U | Completed | No outcome recorded |
| Phase 2 | NCT05142553 | Nov 2021 → May 2023 | COVID-19 | Hipra Scientific, S.L.U | Completed | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05303402 | May 2022 → Jul 2023 | COVID-19 | Hipra Scientific, S.L.U | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05246137 | Feb → Mar 2022 | COVID-19 | Hipra Scientific, S.L.U | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-12-20 | Hipra Scientific, S.L.U | Results HIPRA’s Covid-19 vaccine shows an effective immunological response with no adverse effects in preclinical trials hipra.com ↗
HIPRA’s Covid-19 vaccine showed an effective immunological response, inducing the production of antibodies (IgG and neutralising), a T lymphocyte cell response, and no adverse effects. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-20 | Hipra Scientific, S.L.U | HIPRA’s Covid-19 vaccine shows an effective immunological response with no adverse effects in preclinical trials hipra.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHH-1V | “Here we report the safety, tolerability, and immunogenicity of a recombinant protein RBD fusion heterodimeric vaccine against SARS-CoV-2 (PHH-1V) evaluated in a phase 1-2a...” PMID 37775521 ↗ Sep 20234“A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and well-tolerated in healthy young adults” PMID 37131861 ↗ Apr 2023 “Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)” NCT05305573 ↗ “a recombinant protein RBD fusion heterodimer candidate (PHH-1V)” NCT05246137 ↗ |
| Known as | COVID-19 Vaccine HIPRA | “Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)” NCT05305573 ↗ |
| Modality | Vaccine | “a recombinant protein RBD fusion heterodimeric vaccine against SARS-CoV-2 (PHH-1V)” PMID 37775521 ↗ Sep 2023 |
| Route | Intramuscular | “one intramuscular injection” NCT05246137 ↗ |